Menactra
Description
Menactra vaccine is Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate indicated for active immunization to prevent invasive Meningococcal disease caused by N meningitidis serogroups A, C, Y and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.
Immunization guideline:
Primary Vaccination:
Children 9 through 23 months of age: Two doses, three months apart
Individuals 2 through 55 years of age: A single dose
Booster Vaccination:
A single booster dose may be given to individuals 15 through 55 years of age at continued risk for meningococcal disease, if at least 4 years have elapsed since the prior dose
For latest IAP updates see revised immunization schedule.
Additional information
manufacturer
Sanofi Pasteur
country-of-manufacture
USA
vaccine-type
MeningococcalACYW-135 (conjugate vaccine)
pharmaceutical-form
Liquid
package-size
1 Dose
route-of-administration
Intramuscular
preservative
None
Contraindications
Severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide, diphtheria toxoid or CRM-containing vaccine, or to any component of Menactra vaccine